- Home
- RXRX vs NVAX Comparison
RXRX vs NVAX Comparison
Compare RXRX & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- NVAX
- Stock Information
- Founded
- RXRX 2013
- NVAX 1987
- Country
- RXRX United States
- NVAX United States
- Employees
- RXRX N/A
- NVAX N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RXRX Health Care
- NVAX Health Care
- Exchange
- RXRX Nasdaq
- NVAX Nasdaq
- Market Cap
- RXRX 2.0B
- NVAX 1.3B
- IPO Year
- RXRX 2021
- NVAX 1995
- Fundamental
- Price
- RXRX $5.25
- NVAX $6.80
- Analyst Decision
- RXRX Buy
- NVAX Buy
- Analyst Count
- RXRX 5
- NVAX 5
- Target Price
- RXRX $7.00
- NVAX $16.60
- AVG Volume (30 Days)
- RXRX 32.1M
- NVAX 5.2M
- Earning Date
- RXRX 08-07-2025
- NVAX 08-07-2025
- Dividend Yield
- RXRX N/A
- NVAX N/A
- EPS Growth
- RXRX N/A
- NVAX N/A
- EPS
- RXRX N/A
- NVAX 2.97
- Revenue
- RXRX $59,790,000.00
- NVAX $1,254,962,000.00
- Revenue This Year
- RXRX $23.51
- NVAX $56.85
- Revenue Next Year
- RXRX $53.87
- NVAX N/A
- P/E Ratio
- RXRX N/A
- NVAX $2.29
- Revenue Growth
- RXRX 29.32
- NVAX 25.92
- 52 Week Low
- RXRX $3.79
- NVAX $5.01
- 52 Week High
- RXRX $12.36
- NVAX $17.81
- Technical
- Relative Strength Index (RSI)
- RXRX 55.15
- NVAX 51.68
- Support Level
- RXRX $4.91
- NVAX $6.23
- Resistance Level
- RXRX $5.44
- NVAX $6.90
- Average True Range (ATR)
- RXRX 0.36
- NVAX 0.30
- MACD
- RXRX 0.01
- NVAX 0.01
- Stochastic Oscillator
- RXRX 72.37
- NVAX 67.00
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.